Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Reformulated Mim8 in Healthy Men
NCT05127473Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events. Started Jul 2021; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05127473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127473.